Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

Article Properties
Cite
Santarpia, Libero, et al. “Targeting the MAPK–RAS–RAF Signaling Pathway in Cancer Therapy”. Expert Opinion on Therapeutic Targets, vol. 16, no. 1, 2012, pp. 103-19, https://doi.org/10.1517/14728222.2011.645805.
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012). Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16(1), 103-119. https://doi.org/10.1517/14728222.2011.645805
Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets. 2012;16(1):103-19.
Refrences
Citations
Citations Analysis
The first research to cite this article was titled Explore the Molecular Mechanism of Apoptosis Induced by Tanshinone IIA on Activated Rat Hepatic Stellate Cells and was published in 2012. The most recent citation comes from a 2024 study titled Explore the Molecular Mechanism of Apoptosis Induced by Tanshinone IIA on Activated Rat Hepatic Stellate Cells . This article reached its peak citation in 2022 , with 88 citations.It has been cited in 357 different journals, 27% of which are open access. Among related journals, the Cancers cited this research the most, with 22 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year